The imaging platform powered by Ultreon 1.0 Software
Abbott announced that its new imaging platform powered by Ultreon 1.0 Software, is now CE Marked in Europe. This first-of-its-kind imaging software merges optical coherence tomography (OCT) – an imaging tool that provides physicians with a comprehensive view inside an artery or blood vessel – with the power of artificial intelligence (AI) for enhanced visualisation. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting procedures.
Abbott’s OCT technology uses near-infrared light to provide high-definition, precise imaging from within a blood vessel. OCT imaging also helps improve physicians’ assessment of blockages in those vessels and optimise decisions related to stent selection, placement and deployment. Through integration with Abbott’s new Dragonfly OpStar imaging catheter, Ultreon Software extends the reach of OCT by allowing physicians to capture information from even the most complex patient anatomy.
With the launch of Ultreon Software, Abbott is further leveraging OCT technology to help physicians make better treatment decisions for their patients. Recent data show that physicians altered their treatment strategy in 88 per cent of coronary artery blockages based on new information provided by OCT when used with MLD MAX, a new workflow that helps guide stenting decisions and provide physicians with treatment strategies to optimise stent placement.
“Ultreon’s customisable user interface and AI detection will make decision-making faster and reduce procedural variability, especially for the increasing number of physicians who are learning to utilise OCT imaging over other more traditional imaging technologies,” said Jose Mª de la Torre Hernández, Head of interventional cardiology, Hospital Universitario Marques de Valdecilla, and editor-in-chief of REC: Interventional Cardiology.
“Increased adoption of OCT imaging, when combined with advanced technology like AI, allows cardiologists to have a more precise and measurable way of supporting patients undergoing coronary stent procedures,” says Nick West, Chief Medical Officer and Divisional Vice President of Global Medical Affairs, Abbott’s vascular business.
“Ultreon Software can potentially improve physician and patient experience by utilising a systematic process, reducing variability and increasing the accuracy of diagnosis and application of therapies.”
The new Ultreon Software will be showcased for the first time at EuroPCR on May 18-21, 2021, during Abbott’s ‘Tools and Technique Sessions.’ Abbott also intends to seek approval in the US and Japan.
